Summary
The value of combination chemotherapy with HEXA-CAF was analyzed in 31 patients with histologically documented epithelial ovarian cancer in advanced stages (minimal or gross disease). No patient had been previously treated with chemotherapy. Peritoneoscopy with diaphragmatic inspection, peritoneal cytology, lymphography, and chest X-ray were routinely used in staging and restaging the patients. Complete (CR) plus partial (PR) responses were obtained in 13/31 fully restaged patients (41.9%). CR was recorded in seven patients (22.5%) and PR in six patients (19.3%). Remission duration was significantly longer in patients who achieved CR (20 months) than in those who attained PR (9.5 months)(P<0.01). In all treated patients the median duration of survival was 16.5 months. Survival was significantly longer in patients with CR than in patients who did not achieve CR (P<0.05). Nevertheless, considering the rate of CR in patients with gross disease (20.6%), HEXA-CAF combination seems a useful but not yet ahopeful treatment for patients with advanced ovarian carcinoma.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Beck RE, Boyes DA (1968) Treatment of 126 cases of advanced ovarian carcinoma with cyclophosphamide. Can Med Assoc J 98: 539
Brower MS, Coleman M, Chiarieri DE, Pasmantier MW, Silver RT (1979) Combination chemotherapy of ovarian carcinoma. Proc Am Assoc Cancer Res/Am Soc Clin Oncol 20: 186 (Abstract 751)
Delgado G, Schein P, Macdonald J, Tulholski N, Haidak D (1979) l-PAM vs cyclophosphamide, hexamethylmelamine and 5-fluorouracil (CHF) for advanced ovarian cancer. Proc Am Assoc Cancer Res/Am Soc Clin Oncol 20: 434 (Abstract C-595)
De Palo G, De Lena M, Di Re F, Luciani L, Valagussa P, Bonadonna G (1975) Melphalan versus adriamycin in the treatment of advanced carcinoma of the ovary. Surg Gynecol Obstet 141:899
De Palo G, De Lena M, Bonadonna G (1977) Adriamycin versus adriamycin plus melphalan in advanced ovarian carcinoma. Cancer Treat Rep 61: 355
De Palo G, Musumeci R, Spinelli P, Pilotti S (to be published) Il carcinoma ovarico: quasi uno sconosciuto. II. Staging e fattori prognostici. Argomenti di Oncologia
Ehrlich CE, Einhorn L, Williams SD, Morgan J (1979) Chemotherapy for stage III-IV epithelial ovarian cancer with cis-dichlorodiammineplatinum (II), adriamycin, and cyclophosphamide: a preliminary report. Cancer Treat Rep 63: 281
Myers RA, Belinson J, Yates JW, Krakoff IH (1979) Combination chemotherapy of ovarian carcinoma. Proc Am Assoc Cancer Res/Am Soc Clin Oncol 20: 405 (Abstract C-471)
Neut JP, Van Lindert ACM, Vendrik CPJ, Raozendaal KJ, Struyvenberg A, Pinedo HM (1979) Hexa-CAF combination chemotherapy and other multiple-drug regimens in advanced ovarian carcinoma: present and future. Neth J Med 22: 38
Omura GA, Blessing JA, Buchsbaum HJ, Lathrop J (1979) A randomized trial of melphalan (M) vs melphalan plus hexamethylmelamine (M+H) vs adriamycin plus cyclophosphamide (A+C) in advanced ovarian adenocarcinoma. Proc Am Assoc Cancer Res/Am Soc Clin Oncol 20:358 (Abstract C-279)
Pesando JM, Come SE, Parker LM, Griffiths CT, Canellos GP (1979) cis-Diamminedichloroplatinum (CDDP) therapy of advanced ovarian cancer. Proc Am Assoc Cancer Res/Am Soc Clin Oncol 20:328 (Abstract C-152)
Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, Mantel N, McPherson K, Peto J Smith PG (1979) Design and analysis of randomized clinical trial requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer 35: 1
Russell P (1979a) The pathological assessment of ovarian neoplasms. I. Introduction to the common “epithelial” tumours and analysis of benign “epithelial” tumours. Pathology 11: 5
Russell P (1979b) The pathological assessment of ovarian neoplasms. II. The maligant “epithelial” tumours. Pathology 11: 493
Serov SF, Scully RE, Sobin LH (1973) Histological typing of ovarian tumours. International Histological Classification of Tumours No. 9. World Health Organization, Geneva
Smith J, Rutledge F, Wharton JT (1972) Chemotherapy of ovarian cancer: new approaches to treatment. Cancer 30: 1565
Thigpen T, LaGasse L, Bundy B (1979) Phase II trial of cis-platinum in treatment of advanced ovarian adenocarcinoma. Proc Am Assoc Cancer Res/Am Soc Clin Oncol 20: 84 (Abstract 339)
Vogl SE, Greenwald E, Kaplan BH (1979) The “CHAD” regimen [cyclophosphamide (C), hexamethylmelamine (H), adriamycin (A) and diamminedichloroplatinum (D)] in advanced ovarian cancer. Proc Am Assoc Cancer Res/Am Soc Clin Oncol 20:384 (Abstract C-385)
Wharton TJ, Rutledge F, Smith JP, Herson J, Hodge PM (1979) Hexamethylmelamine: an evaluation of its role in the treatment of ovarian cancer. Am J Obstet Gynecol 133: 833
Williams CJ, Stevenson KE, Whitehouse JMA (1979) Pharmacokinetics and toxicity of cis-diammine-dichloroplatinum (CDDP) given by IV bolus 24 or 48 h infusion. Proc Am Assoc Cancer Res/Am Soc Clin Oncol 20: 317 (Abstract C-108)
Young RC, Chabner BA, Hubbard SP, Fisher RI, Bender RA, Anderson T, Simon RM, Canellos GP, De Vita VT, Jr (1978) Advanced ovarian adenocarcinoma. A prospective clinical trial of melphalan (l-PAM) versus combination chemotherapy. N Engl J Med 299: 1261
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
De Palo, G., Demicheli, R., Valagussa, P. et al. Prospective study with HEXA-CAF combination in ovarian carcinoma. Cancer Chemother. Pharmacol. 5, 157–161 (1981). https://doi.org/10.1007/BF00258473
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00258473